These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36233084)

  • 1. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine.
    Lin SL; Lin CY; Lee W; Teng CF; Shyu WC; Jeng LB
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
    Buck E; Mulvihill M
    Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
    King H; Aleksic T; Haluska P; Macaulay VM
    Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.
    Ngo MT; Jeng HY; Kuo YC; Diony Nanda J; Brahmadhi A; Ling TY; Chang TS; Huang YH
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
    Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting insulin-like growth factor axis in hepatocellular carcinoma.
    Wu J; Zhu AX
    J Hematol Oncol; 2011 Jul; 4():30. PubMed ID: 21729319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
    Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
    Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IGF-1 signaling pathways in gynecologic malignancies.
    Bruchim I; Werner H
    Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
    Wojtalla A; Salm F; Christiansen DG; Cremona T; Cwiek P; Shalaby T; Gross N; Grotzer MA; Arcaro A
    PLoS One; 2012; 7(10):e47109. PubMed ID: 23056595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of IGF/IGF-1R signaling in the regulation of cancer stem cells.
    Liu F; Ye S; Zhao L; Niu Q
    Clin Transl Oncol; 2024 Dec; 26(12):2924-2934. PubMed ID: 38865036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL14 Maintains hESC Self-Renewal through Binding to IGF-1R and Activation of the IGF-1R Pathway.
    Cheng CL; Yang SC; Lai CY; Wang CK; Chang CF; Lin CY; Chen WJ; Lin PY; Wu HC; Ma N; Lu FL; Lu J
    Cells; 2020 Jul; 9(7):. PubMed ID: 32708730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the pathway to insulin-like growth factor system targeting in cancer.
    Rosenzweig SA; Atreya HS
    Biochem Pharmacol; 2010 Oct; 80(8):1115-24. PubMed ID: 20599789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications.
    Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
    Pediatr Endocrinol Rev; 2013 Jul; 10(4):473-84. PubMed ID: 23957198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.